Click here to view online. Add this email to your safelist.

AstraZeneca logo

Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose

28 July 2021

Rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of Vaxzevria are comparable to the background rate in an unvaccinated population. 

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2021

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.